Abstract
The phylogenetic, therapeutic and experimental evidences suggest that the circulating prolactin levels alter the gastric contractility in experimental animals as well as in patients suffering from gastric dyspepsia. The dopamine antagonists are used in the treatment dysmotility-like dyspepsia and could relieve the dyspeptic symptoms. These drugs are potent stimulants for the release of prolactin. Further, in non-ulcer dyspepsia, a primary dysfunction of pituitary lactotrophs has been proposed. Thus, the dysmotility-like gastric dyspepsia is associated with the deficiency of endogenous prolactin levels so as to reduce gastric contractions. This concept brings a new line of thinking in the pathogenesis of dysmotility-like gastric dyspepsia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
